Australia-based Firebrick Pharma has secured firm commitments from strategic investors for approximately $732k, through the placement of approximately 20.9 million fully paid ordinary shares at an issue price of $0.035 (3.5 cents) per share.
The investment was anchored by the company’s licensing partner in the Philippines through Pharma Nutria N.A. Inc., a member of the S. V. More Group of Companies. The PN-NA investment was $631,750, which increases PN-NA’s holding in Firebrick to just over 10%.
The remaining $100,000 is being invested by an existing sophisticated investor who has supported the company since its listing on the ASX. These investments follow on from the ASX announcements of 29 September 2026 and 7 October 2026 where the company announced its intention to enter the US retail pharmacy market for Nasodine products.
Firebrick Pharma has developed and commercialised Nasodine, a Phase 3 proven PVP-I nasal spray that kills all respiratory viruses.
The proceeds from the placement will be applied for new production for US retail distribution; for production and launch in Singapore of a new Nasodine product; and for working capital.
